AG Eilers
Prof. Dr. Martin Eilers
Lehrstuhl für Biochemie und Molekularbiologie
Biozentrum
Am Hubland
97074 Würzburg
Tel: 0931 31-84111
Fax: 0931 31-84113
martin.eilers@biozentrum.uni-wuerzburg.de
Many cancers are life-threatening diseases and there is an urgent need for novel therapeutic strategies. Our group works on the human MYC protein family, which is involved in the development of the majority of all human cancers. Our aim is both to understand the function of MYC proteins and explore new strategies to inhibit their function.
Publications
Latest:
Otto C, Kastner C, Schmidt S, Uttinger K, Baluapuri A, Denk S, Rosenfeldt MT, Rosenwald A, Roehrig F, Ade CP, Schuelein-Voelk C, Diefenbacher ME, Germer CT, Wolf E, Eilers M, Wiegering A (2022) RNA polymerase I inhibition induces terminal differentiation, growth arrest and vulnerability to senolytics in colorectal cancer cells. Mol Oncol doi: 10.1002/1878-0261.13265
Mainz L, Sarhan M, Roth S, Sauer U, Kalogirou C, Eckstein M, Gerhard-Hartmann E, Seibert HD, Voelker HU, Geppert C, Rosenwald A, Eilers M, Schulze A, Diefenbacher M, Rosenfeldt MT (2022) Acute systemic knockdown of Atg7 is lethal and causes pancreatic destruction in shRNA transgenic mice. Autophagy: 1-14. doi: 10.1080/15548627.2022.2052588.
Papadopoulos D, Solvie D, Baluapuri A, Endres, T, Ha S., Herold S, Kalb J, Giansanti C, Schülein-Völk C, Ade CP, Schneider C, Gaballa A, Vos S, Fischer U, Dobbelstein M, Wolf E., Eilers M (2021) MYCN recruits the nuclear exosome complex to RNA polymerase II to prevent transcription‑replication conflicts. Mol Cell https://doi.org/10.1016/j.molcel.2021.11.002
Narain A, Bhandare P, Adhikari B, Backes S, Eilers M, Dolken L, Schlosser A, Erhard* F, Baluapuri* A, Wolf* E (2021) Targeted protein degradation reveals a direct role of SPT6 in RNAPII elongation and termination. Mol Cell 81: 3110-3127 e14 *corresponding authors
Cossa G, Parua PK, Eilers M, Fisher RP (2021) Protein phosphatases in the RNAPII transcription cycle: erasers, sculptors, gatekeepers, and potential drug targets. Genes Dev 35: 658-676
Roeschert I, Poon E, Henssen AG, Garcia HD, Gatti M, Giansanti C, Jamin Y, Ade CP, Gallant P, Schulein-Volk C, Beli P, Richards M, Rosenfeldt M, Altmeyer M, Anderson J, Eggert A, Dobbelstein M, Bayliss R, Chesler* L, Buchel* G, Eilers* M (2021) Combined inhibition of Aurora-A and ATR kinase results in regression of MYCN-amplified neuroblastoma. Nat Cancer 2: 312-326 *corresponding authors
Wolpaw AJ, Bayliss R, Buchel G, Dang CV, Eilers M, Gustafson WC, Hansen GH, Jura N, Knapp S, Lemmon MA, Levens D, Maris JM, Marmorstein R, Metallo SJ, Park JR, Penn LZ, Rape M, Roussel MF, Shokat KM, Tansey WP, Verba KA, Vos SM, Weiss WA, Wolf E, Mosse YP (2021) Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers. Cancer Res 81: 1627-1632
Endres T, Solvie D, Heidelberger JB, Andrioletti V, Baluapuri A, Ade CP, Muhar M, Eilers U, Vos SM, Cramer P, Zuber J, Beli P, Popov N, Wolf E, Gallant P, Eilers M (2021) Ubiquitylation of MYC couples transcription elongation with double-strand break repair at active promoters. Mol Cell 81: 830-844 e13
Krenz B, Gebhardt-Wolf A, Ade CP, Gaballa A, Roehrig F, Vendelova E, Baluapuri A, Eilers U, Gallant P, D'Artista L, Wiegering A, Gasteiger G, Rosenfeldt MT, Bauer S, Zender L, Wolf E, Eilers M (2021) MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma. Cancer Res 81: 4242-4256
